AALL1521; Ruxolitinib and Chemotherapy for Patients with JAK-Mutant B-ALL

AALL1521; Ruxolitinib and Chemotherapy for Patients with JAK-Mutant B-ALL

Contact

 If you are interested in participating in the study or want to learn more, please contact: Contact us
This study is no longer recruiting.

Description
This study is testing the safety and effectiveness of adding a targeted therapy (ruxolitinib) to standard chemotherapy for children, adolescents, and young adults with high-risk acute lymphoblastic leukemia with CRLF2 and other JAK pathway mutations.

Eligibility and criteria
IRB Number:
16-012888
Clinical trial phase:
Phase II
Official title:
AALL1521; A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia (INCB 18424-269)

What to expect

Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.